Pulmonx Deferred Long Term Liab from 2010 to 2024
| LUNG Stock | USD 6.61 0.18 2.65% |
Deferred Long Term Liabilities | First Reported 2010-12-31 | Previous Quarter 84.6 K | Current Value 80.4 K | Quarterly Volatility 727.8 K |
Check Pulmonx Corp financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Pulmonx Corp's main balance sheet or income statement drivers, such as Interest Expense of 3.4 M, Selling General Administrative of 94.3 M or Total Revenue of 72.1 M, as well as many indicators such as Price To Sales Ratio of 6.7, Dividend Yield of 0.0 or PTB Ratio of 4.3. Pulmonx financial statements analysis is a perfect complement when working with Pulmonx Corp Valuation or Volatility modules.
Pulmonx | Deferred Long Term Liab |
Latest Pulmonx Corp's Deferred Long Term Liab Growth Pattern
Below is the plot of the Deferred Long Term Liab of Pulmonx Corp over the last few years. It is liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue. Pulmonx Corp's Deferred Long Term Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Pulmonx Corp's overall financial position and show how it may be relating to other accounts over time.
| Deferred Long Term Liab | 10 Years Trend |
|
Deferred Long Term Liab |
| Timeline |
Pulmonx Deferred Long Term Liab Regression Statistics
| Arithmetic Mean | 1,065,865 | |
| Geometric Mean | 550,028 | |
| Coefficient Of Variation | 68.29 | |
| Mean Deviation | 662,847 | |
| Median | 1,563,000 | |
| Standard Deviation | 727,832 | |
| Sample Variance | 529.7B | |
| Range | 1.5M | |
| R-Value | (0.82) | |
| Mean Square Error | 190.3B | |
| R-Squared | 0.67 | |
| Significance | 0.0002 | |
| Slope | (132,860) | |
| Total Sum of Squares | 7.4T |
Pulmonx Deferred Long Term Liab History
About Pulmonx Corp Financial Statements
Pulmonx Corp stakeholders use historical fundamental indicators, such as Pulmonx Corp's Deferred Long Term Liab, to determine how well the company is positioned to perform in the future. Although Pulmonx Corp investors may analyze each financial statement separately, they are all interrelated. For example, changes in Pulmonx Corp's assets and liabilities are reflected in the revenues and expenses on Pulmonx Corp's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Pulmonx Corp. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Deferred Long Term Liabilities | 84.6 K | 80.4 K |
Currently Active Assets on Macroaxis
When determining whether Pulmonx Corp is a strong investment it is important to analyze Pulmonx Corp's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Pulmonx Corp's future performance. For an informed investment choice regarding Pulmonx Stock, refer to the following important reports:Check out the analysis of Pulmonx Corp Correlation against competitors. For more detail on how to invest in Pulmonx Stock please use our How to Invest in Pulmonx Corp guide.You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pulmonx Corp. If investors know Pulmonx will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pulmonx Corp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.47) | Revenue Per Share 2.043 | Quarterly Revenue Growth 0.154 | Return On Assets (0.20) | Return On Equity (0.52) |
The market value of Pulmonx Corp is measured differently than its book value, which is the value of Pulmonx that is recorded on the company's balance sheet. Investors also form their own opinion of Pulmonx Corp's value that differs from its market value or its book value, called intrinsic value, which is Pulmonx Corp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pulmonx Corp's market value can be influenced by many factors that don't directly affect Pulmonx Corp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pulmonx Corp's value and its price as these two are different measures arrived at by different means. Investors typically determine if Pulmonx Corp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pulmonx Corp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.